DermTech, Inc. DMTKQ
- Market cap
- $3.3M
- P/E
- 0.0×
Follow DMTKQ
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 19.10 | 19.44 | 4.52 | 8.69 | 15.15 | 1.55 | 1.12 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | — | 19.80 | 20.50 | 23.24 | 37.37 | 84.49 | 17.68 | 6.44 |
High Price
|
|||
| — | — | — | 2 | 2 | 64 | 118 | 258 | 279 | 208 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 2 | 3 | 6 | 12 | 15 | 15 |
Revenue
|
|||
| — | — | 0.00% | 0.00% | (7.58%) | 1.78% | (1.63%) | 10.76% | 4.46% | 1.80% |
Gross Margin
|
|||
| — | — | 0 | 1 | (10) | (20) | (36) | (78) | (117) | (101) |
EBT
|
|||
| — | — | 0.00% | 0.00% | (409.66%) | (598.39%) | (619.83%) | (661.72%) | (803.71%) | (659.57%) |
EBT Margin
|
|||
| — | — | 0 | 0 | (10) | (20) | (36) | (78) | (117) | (101) |
Net Income
|
|||
| — | — | 0 | 0 | 1 | 2 | 0 | 3 | 5 | 5 |
Depreciation
|
|||
| — | — | — | 0.00 | 0.55 | 0.48 | 0.35 | 0.41 | 0.48 | 0.47 |
Revenue/Sh
|
|||
| — | — | — | 0.03 | (2.27) | (2.81) | (2.08) | (2.71) | (3.88) | (3.09) |
Earnings/Sh
|
|||
| — | — | 0.00 | 0.00 | (1.72) | (2.54) | (1.69) | (2.15) | (3.17) | (2.36) |
Cash Flow/Sh
|
|||
| — | — | 0.00 | 0.00 | 0.00 | (0.03) | (0.11) | (0.09) | (0.11) | (0.03) |
Capex/Sh
|
|||
| — | — | 0.00 | 0.00 | (1.73) | (2.57) | (1.80) | (2.24) | (3.28) | (2.39) |
Free CF/Sh
|
|||
| — | — | 0.00 | 0.01 | (1.21) | 1.78 | 3.64 | 7.95 | 4.41 | 1.75 |
Book Value/Sh
|
|||
| — | — | — | 2 | 4 | 7 | 17 | 29 | 30 | 33 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | 25.82 | 93.60 | 38.55 | 3.77 | 3.54 |
PS Ratio
|
|||
| — | — | — | — | 0.00 | 6.96 | 8.91 | 1.99 | 0.41 | 0.95 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | 21.40 | 83.08 | 19.54 | (4.92) | (0.11) |
EV/Sales
|
|||
| — | — | — | — | (60.35) | (4.00) | (16.02) | (3.57) | 0.72 | 0.02 |
EV/FCF
|
|||
| — | — | 0 | (1) | (8) | (18) | (29) | (62) | (95) | (77) |
Op' Cash Flow
|
|||
| — | — | 0 | 0 | 0 | 0 | (2) | (3) | (3) | (1) |
Capex
|
|||
| — | — | 0 | (1) | (8) | (18) | (31) | (65) | (99) | (78) |
FCF
|
|||
| — | — | 0 | 0 | (5) | 11 | 61 | 221 | 120 | 48 |
Working Cap'
|
|||
| — | — | — | — | 1 | — | 2 | 0 | 0 | 0 |
Total Debt
|
|||
| — | — | 0 | 0 | (4) | (15) | (62) | (225) | (126) | (56) |
Net Debt
|
|||
| — | — | 0 | 0 | (5) | 12 | 62 | 230 | 132 | 57 |
Sh' Equity
|
|||
| — | — | (0.10%) | 1.17% | (13.12%) | (131.35%) | (82.91%) | (49.25%) | (51.81%) | (62.28%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,040.52%) | (1,182.97%) | (4,806.29%) |
ROIC
|
|||
| — | — | (1.03%) | 0.00% | 5,636.06% | (230.20%) | (98.15%) | (53.74%) | (64.46%) | (106.46%) |
ROE
|
|||
DermTech, Inc. peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ISPC iSpecimen Inc. | $3.1M | 0.0× | Compare |
| NOTVQ Inotiv, Inc. | $2.8M | 0.0× | Compare |
| AWHL Aspira Women's Health Inc. | $2.4M | 0.0× | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| XWEL XWELL, Inc. | $7.6M | 0.0× | Compare |
| NDRA ENDRA Life Sciences Inc. | $8.9M | 0.0× | Compare |
| BIAF bioAffinity Technologies, Inc. | $9.0M | 0.0× | Compare |
| PRPH ProPhase Labs, Inc. | $1.2M | 0.0× | Compare |
DermTech, Inc. (DMTKQ) key facts
- DermTech, Inc. (DMTKQ) is a Diagnostics & Research company in the Healthcare sector.
- DermTech, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.3 million, up 5.36% from fiscal 2022.
- DermTech, Inc. reported a net loss of $100.9 million, or a loss of $3.09 per share, for fiscal 2023.
- Return on equity was −106.5% and debt-to-equity 0.00.
DermTech, Inc. (DMTKQ) Latest News
15 Oct
Cynthia Collins appointed to MaxCyte's Board of Directors as a non-executive director. Appointment may moderately influence MaxCyte's operations and growth.
30 Aug
DermTech, Inc. completes asset sale to DERM-JES Holdings, LLC, operations to continue under new ownership and management. The asset sale and change in ownership may moderately influence DermTech's future operations and competitive positioning.
20 Jun
Dermtech files for Chapter 11 bankruptcy, lays off 20% of staff to find a buyer for its cancer test technology. Chapter 11 bankruptcy filing and layoffs are expected to significantly impact DermTech's future and market performance.
18 Jun
DermTech, Inc. filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware, intending to continue operations and sell assets while implementing a reduction in force. The chapter 11 filing and strategic alternatives review process are expected to significantly impact DermTech's future and market performance.
14 May
DermTech reports first-quarter 2024 financial results. Financial performance may moderately influence market sentiment.
19 Apr
Dermtech to cut 100 jobs, explore strategic options to preserve cash. Significant impact likely on future and performance due to workforce reduction, strategic review, and potential delisting from Nasdaq.
18 Apr
DermTech explores strategic alternatives and implements restructuring plan. The strategic review process, potential workforce reduction, and engagement of restructuring advisor indicate significant impact on future operations and market performance.
8 Mar
DermTech presents research abstracts at AAD Annual Meeting and new research published in Journal of Investigative Dermatology. Research findings on skin genomics technology and skin cancer risk have the potential to significantly impact DermTech's future product innovation and competitive positioning.
3 Mar
DermTech, Inc. (NASDAQ:DMTK) shares crashed 31% to US$0.87 after yearly results in line with analyst forecasts. The article suggests a moderately noticeable influence on DermTech's future performance and market sentiment.
2 Mar
DermTech, Inc. reported Q4 2023 earnings, missing expectations with a net loss of $19.1 million. The financial results and strategic initiatives discussed in the article are expected to moderately influence DermTech, Inc.'s future performance.
29 Feb
DermTech reported fourth-quarter 2023 financial results, showing increased ASP for the DermTech Melanoma Test and revenue growth. The financial results and strategic actions outlined in the article are expected to significantly impact DermTech's future performance and market positioning.
DermTech, Inc. (DMTK) reports Q4 loss, misses revenue estimates. The article indicates a moderately noticeable influence on DermTech, Inc.'s future and market performance due to the missed revenue estimates and quarterly loss.
13 Feb
DermTech to discuss fourth-quarter 2023 financial results in conference call and webcast on February 29, 2024. The announcement of financial results and discussion in a conference call can significantly impact investor sentiment and the company's trajectory.
31 Jan
DermTech announces additional restructuring actions to focus on revenue growth and streamline operations. The restructuring actions and focus on revenue growth are expected to significantly impact DermTech's future performance and market positioning.
18 Jan
DermTech reports positive results from a study evaluating the DermTech Melanoma Test across all skin types. Study results demonstrate significant potential impact on DermTech's future market performance and competitive positioning.
16 Jan
DermTech had a cash runway of 9 months as of September 2023, with a market cap of US$49m and burnt through US$89m last year. The article highlights significant funding difficulties and potential need for more cash, which could fundamentally alter the company's trajectory.
8 Jan
DermTech reports positive results from Trust 2 Study for Melanoma Test, showing high NPV and clinical utility. The positive results from the Trust 2 Study are expected to significantly impact DermTech's future performance and market positioning.
3 Nov
DermTech, Inc. beats earnings expectations with reported EPS of $-0.57 compared to expectations of $-0.68. Significant impact likely on future performance with improved financial metrics and strategic initiatives.
2 Nov
DermTech reports third-quarter 2023 financial results, showing growth in ASP and test revenue. The financial results and strategic progress outlined in the article are expected to have a significant impact on DermTech's future performance and market positioning.
DermTech Inc (DMTK) reports 10% increase in total revenue for Q3 2023. The increase in revenue and improvement in key performance indicators are expected to moderately influence the company's financial performance and competitive positioning.
12 Oct
DermTech to release third-quarter 2023 financial results on November 2, 2023. The financial results announcement may moderately influence market sentiment and financial performance.
21 Sep
DermTech grants new CCO Mark Aguillard inducement award under NASDAQ Listing Rule 5635(c)(4). The equity award and stock options granted to the new CCO could moderately influence DermTech's future financial performance and competitive positioning.
19 Sep
DermTech announces contracts with Highmark for the foundational assay of its DermTech Melanoma Test. Contracts with Highmark and increased access to DMT test can significantly impact DermTech's future market performance.